Glycogen synthase kinase 3β (GSK-3β) inhibitors - a patent update (2019-2024) [0.03%]
关于糖原合酶激酶3β(GSK-3β)抑制剂的专利更新(2019-2024)
Swanand Vinayak Joshi,Devandla Soujanya,Manchella Sai Supriya et al.
Swanand Vinayak Joshi et al.
Introduction: Glycogen synthase kinase-3β (GSK-3β) is a proline-directed serine/threonine kinase identified over 40 years ago. It is the key enzyme involved in glycogen biosynthesis and is expressed in all human tissues...
Overcoming triple mutant EGFR-tyrosine kinase barriers in the therapeutics of non-small cell lung cancer: a patent review on fourth-generation inhibitors (2017-2024) [0.03%]
克服EGFR-酪氨酸激酶三联突变体在非小细胞肺癌治疗中的屏障：第四代抑制剂（2017-2024）专利综述
Narendra R Nagpure,Harun M Patel
Narendra R Nagpure
Introduction: Non-small cell lung cancer (NSCLC) remains a leading cause of cancer mortality, with 'epidermal growth factor receptor (EGFR)' mutations being a primary driver of tumor progression. This review highlights th...
Recent advances in tropomysosin receptor kinase (TRK) inhibitors: a 2023-2024 patent landscape review [0.03%]
2023-2024年神经生长因子受体酪氨酸激酶(TRK)抑制剂专利布局分析进展
Minh Le,Elena Timakova,Ralf Schirrmacher et al.
Minh Le et al.
Introduction: The rise of tissue-agnostic therapies has revolutionized cancer treatment, with therapies targeting NTRK fusions leading the way. TRK inhibitors like larotrectinib and entrectinib marked a paradigm shift - p...
Daniela Rodrigues de Oliveira,Heber Victor Tolomeu,Carlos Alberto Manssour Fraga et al.
Daniela Rodrigues de Oliveira et al.
Introduction: Rho-associated protein kinases (ROCK) play a crucial role in various biological processes, making them a valuable therapeutic target. Recent FDA approvals of ROCK-targeting drugs have brought renewed focus t...
Dounan Xu,Jiahuan Zhong,Yuhan Zeng et al.
Dounan Xu et al.
Introduction: The Transcriptional Enhanced Associated Domain (TEAD) family has attracted increasing attention due to its crucial role in the Hippo signaling pathway, which regulates cell growth, division, survival, differ...
An updated patent review of rearranged during transfection (RET) kinase inhibitors (2022-present) [0.03%]
2022年以来 RET 蛋白激酶抑制剂专利进展分析
Daniel Armstrong,Maha Hanafi,Brendan Frett
Daniel Armstrong
Introduction: Rearranged during transfection (RET) is a receptor tyrosine kinase essential for cell signaling processes such as proliferation, differentiation, and migration. RET alterations, including point mutations and...
Markus Egner,Daniel Merk
Markus Egner
Background: Nuclear receptor related 1 (Nurr1) is a ligand-activated transcription factor and considered as neuroprotective and anti-neuroinflammatory target. Several lines of evidence support potential of Nurr1 modulatio...
An updated patent review on rational combinations of HDAC inhibitors for cancer chemotherapy (2020 - present): part 2 - patent published [0.03%]
组蛋白去乙酰化酶抑制剂合理联合治疗癌症化疗的专利更新（2020-至今）：已公布专利部分(二)
Yugal Kishor Shukla,Vandana,Vivekananda Mandal et al.
Yugal Kishor Shukla et al.
Introduction: The emergence of drug resistance poses a serious threat to cancer chemotherapy. by a single agent. Tumor cell heterogeneity, mutation and/or desensitization of receptor render monotherapy ineffective. Combin...
Formyl peptide receptor modulators: a patent review and potential applications for inflammatory diseases (2021-2024) [0.03%]
甲醛肽受体调节剂的专利回顾及其在炎症性疾病中的潜在应用（2021-2024）
Yung-Fong Tsai,Shun-Chin Yang,Tsong-Long Hwang
Yung-Fong Tsai
Introduction: Formyl peptide receptors (FPRs) belong to the family of class A G-protein-coupled receptors that are important for immune modulation and inflammation and are emerging as potential therapeutic targets for sev...
A patent review of IDO1 inhibitors for cancer (2023 - present): an update [0.03%]
IDO1抑制剂的癌症专利回顾（2023年至今）：更新版
Hanyue Qiu,Yiheng Yin,Ziyu Qin et al.
Hanyue Qiu et al.
Introduction: Indoleamine 2,3-dioxygenase 1 (IDO1) is a promising target in cancer immunotherapy, yet its application faces significant challenges due to complex mechanisms of action. Recent advancements in IDO1 inhibitor...